WO2006029065A1 - Promedicaments a base d'agents d'inactivation de l'o6-alkylguanine-adn alkyltransferase, clivables par la beta-glucuronidase - Google Patents

Promedicaments a base d'agents d'inactivation de l'o6-alkylguanine-adn alkyltransferase, clivables par la beta-glucuronidase Download PDF

Info

Publication number
WO2006029065A1
WO2006029065A1 PCT/US2005/031506 US2005031506W WO2006029065A1 WO 2006029065 A1 WO2006029065 A1 WO 2006029065A1 US 2005031506 W US2005031506 W US 2005031506W WO 2006029065 A1 WO2006029065 A1 WO 2006029065A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
substituted
group
benzyl
Prior art date
Application number
PCT/US2005/031506
Other languages
English (en)
Inventor
Robert C. Moschel
Natalia A. Loktionova
Guangping Wei
Anthony E. Pegg
Original Assignee
Goverment Of The United States Of America Represented By The Secretary, Department Of Health And Human Services
The Pen State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goverment Of The United States Of America Represented By The Secretary, Department Of Health And Human Services, The Pen State Research Foundation filed Critical Goverment Of The United States Of America Represented By The Secretary, Department Of Health And Human Services
Priority to AU2005282562A priority Critical patent/AU2005282562A1/en
Priority to EP05794349A priority patent/EP1807438A1/fr
Priority to CA002579660A priority patent/CA2579660A1/fr
Publication of WO2006029065A1 publication Critical patent/WO2006029065A1/fr
Priority to US11/683,310 priority patent/US7825096B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Definitions

  • the present invention relates to prodrugs of inactivators of 0 6 -alkylguanine-DNA alkyltransferase (AGT).
  • AGT alkylguanine-DNA alkyltransferase
  • the prodrugs are cleaved by the beta-glucuronidase enzyme found in tumor cells or co-administered to the patient, and are targeted for use in cancer treatment in combination with an antineoplastic alkylating agent such as l,3-bis(2-chloroethyl)-l- nitrosourea (BCNU) or temozolomide.
  • BCNU l,3-bis(2-chloroethyl)-l- nitrosourea
  • AGT is a DNA repair protein. AGT removes alkyl and aralkyl groups that become attached at the Opposition of guanine in DNA following exposure to mutagenic and/or carcinogenic alkylating agents. It does so by bringing about a stoichiometric transfer of the group attached to the Opposition of a guanine residue in DNA to a cysteine residue within the AGT protein. Pegg, Cancer Research 50: 6119-6129 (1990). Accordingly, AGT is beneficial to a normal cell because it removes the adducts that are formed in DNA by toxic, mutagenic and carcinogenic agents, thereby restoring the DNA to its original state and helping to prevent DNA mutations that can lead to initiation of tumor formation.
  • AGT is also beneficial to a cancerous cell because it also removes those adducts that are formed at the Opposition of guanine in DNA by antineoplastic alkylating agents, such as monofunctional methylating agents, e.g., procarbazine, dacarbazine and temozolomide, and chloroethylating agents, i.e., chloroethylnitrosoureas (CENUs), such as BCNU, ACNU, CCNU, and MeCCNU.
  • CENUs chloroethylnitrosoureas
  • Pegg et al Prog. Nucleic Acid Research Molec. Biol. 51 : 167-223 (1995).
  • the resulting alkylated AGT molecule is consequently inactivated and is unable to carry out subsequent dealkylation reactions.
  • the presence of more AGT in a cell increases its capacity to repair DNA by this mechanism compared to a cell that has less AGT.
  • the other route is direct and involves the use of an adjuvant, i.e., an inactivator of AGT, such as an (9 6 -aralkylguanine, e.g., O ⁇ - benzylguanine; see, for example, Moschel et al., U.S. Patent Nos. 5,091,430; 5,352,669; 5,358,952; 5,525,606; 5,691,307; 5,753,668; 5,916,894; 5,958,932; 6,060,458; 6,172,070; 6,303,604; 6,333,331 ; and 6,436,945.
  • an adjuvant i.e., an inactivator of AGT
  • an (9 6 -aralkylguanine e.g., O ⁇ - benzylguanine
  • Figure IA depicts the concentration of prodrugs 1 (open squares) and 2 (open circles); and of O 6 -benzylguanine (closed squares) and ⁇ 2 6 -benzyl-2'-deoxyguanosme (closed circles), which were produced by the enzymatic cleavage of the prodrugs, as a function of time in contact with 10 units/mL bovine liver ⁇ -glucuronidase.
  • prodrugs 1 and 2 see paragraph 0057.
  • Figure IB depicts the concentration of prodrugs 1 (open squares) and 2 (open circles); and the concentration of (9 6 -benzylguanme (closed squares) and ⁇ 9 6 -benzyl-2'- deoxyguanosine (closed circles), which were produced by the enzymatic cleavage of the prodrugs, as a function of time in contact with 0.2 units/mL E. coli ⁇ -glucuronidase.
  • Figure 2A depicts the % remaining activity of AGT as a function of the concentration of prodrug 1 in the absence of ⁇ -glucuronidase (closed squares) and in the presence of bovine liver ⁇ -glucuronidase: 20 units/mL of ⁇ -glucuronidase (closed circles) and 200 units/mL of ⁇ -glucuronidase (open squares).
  • Figure 2B depicts the % remaining activity of AGT as a function of the concentration of prodrug 2 in the absence of ⁇ -glucuronidase (closed squares) and in the presence of bovine liver ⁇ -glucuronidase: 20 units/mL of ⁇ -glucuronidase (closed circles) and 200 units/mL of ⁇ -glucuronidase (open squares).
  • Figure 3 depicts the % survival of HT29 cells as a function of the concentration of prodrug in a two-hour exposure to BCNU (40 ⁇ M) after prodrug pretreatment.
  • Prodrug 2 (open squares) and prodrug 1 (open circles) were incubated for 5 hr in cell medium containing no ⁇ -glucuronidase; and prodrug 2 was incubated for 14 hr in cell culture containing bovine liver ⁇ -glucuronidase at 20 units/mL of medium (closed squares); prodrug 1 was incubated in cell culture containing bovine liver ⁇ -glucuronidase at 20 units/mL of medium for 7 hr (closed circles) or 14 hr (closed triangles).
  • the present invention provides for ameliorating a disadvantage of some of the known 0 6 -alkylguanine-DNA alkyltransferase inactivators.
  • the present invention provides prodrugs of AGT inactivators.
  • the prodrug includes a glycosyl residue, e.g., glucuronosyl, which is cleavable by the ⁇ -glucuronidase enzyme, and which is either administered and/or found on tumor cells.
  • the cleavage by the enzyme releases the inactivator in the vicinity of the tumor cells.
  • the inactivator is more selective for tumor cells and toxicity to the patient is therefore minimized.
  • the present invention further provides a pharmaceutical composition comprising a prodrug of the invention and a pharmaceutically acceptable carrier.
  • the present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent that causes cytotoxic lesions at the Opposition of guanine.
  • the method comprises administering to the mammal an effective amount of a prodrug and antineoplastic alkylating agent, and optionally the ⁇ -glucuronidase enzyme.
  • the present invention also provides a method of inactivating AGT in a tumor cell comprising contacting said tumor cell with an effective amount of a compound or prodrug of the invention and an effective amount of a ⁇ -glucuronidase enzyme.
  • the present invention is predicated on the concept that enzymatic conversion of a prodrug to an active drug in the vicinity of a tumor cell provides an approach for delivering an inactivator of AGT more selectively to tumor cells versus normal cells of a host.
  • This approach relies on activation by enzymes that are expressed or released by tumor cells, ⁇ - Glucuronidase is an example of a lysosomal hydrolase that is released from necrotic tumor cells found within poorly vascularized regions of tumor masses (Bosslet et al., Tumor Targeting 1995, 1, 45-50; Cancer Res. 1998, 55, 1195-1201; and de Graaf et al., Curr. Pharm. Design 2002, 8, 1391-1403).
  • the present invention provides a compound (or prodrug) of the formula: A — B — C, wherein A is a glucuronosyl residue linked through its 1 -oxygen to the phenyl ring of B; B is a benzyloxycarbonyl group, optionally ring- substituted with one or more electron withdrawing groups; and C is an inactivator of O 6 - alkylguanine-DNA alkyltransferase (AGT) linked to the carbonyl of B, or a pharmaceutically acceptable salt thereof.
  • A is a glucuronosyl residue linked through its 1 -oxygen to the phenyl ring of B
  • B is a benzyloxycarbonyl group, optionally ring- substituted with one or more electron withdrawing groups
  • C is an inactivator of O 6 - alkylguanine-DNA alkyltransferase (AGT) linked to the carbonyl of B, or a pharmaceutically acceptable salt thereof.
  • the glucuronosyl residue (A) can be any suitable enzymatically cleavable poly- oligo, or monosaccharide.
  • the glucuronosyl residue is a D-glucuronosyl residue.
  • the hydroxyl groups of the glucuronosyl residue may be free or protected, e.g., by an ester group that is removed enzymatically or hydrolyzed spontaneously, such as an acetyl or mono-, di-, or trihaloacetyl protective group, with the halogen being fluorine or chlorine, or benzyl protective group.
  • the protective group may be released to provide a substrate for the ⁇ -glucuronidase enzyme.
  • the acid group of the prodrug may be converted to a salt such as a sodium salt.
  • prodrugs of certain drugs e.g., anthracyclines and nitrogen mustards, which contain a glucuronic acid residue linked through a self-immolating linker are cleavable by the ⁇ -glucuronidase enzyme.
  • anthracyclines and nitrogen mustards which contain a glucuronic acid residue linked through a self-immolating linker are cleavable by the ⁇ -glucuronidase enzyme.
  • the electron withdrawing group can be present on the phenyl ring of B at any suitable position, for example, the meta, or preferably ortho, position relative to the oxygen linking B to the glucuronosyl residue. Any suitable electron-withdrawing group (B) can be employed.
  • electron withdrawing groups include nitro, halo, alkylsulfonyl, cyano, trifluoroalkoxy, trifluoroalkylthio, alkylcarbonyloxy, nitroso, formyl, alkoxycarbonyl, alkylcarbonyl, thiol, sulfamoyl, alkylsulfamoyl, chloroalkyl, ammonium, hydroxyalkyl, phenyl, N,N-dialkylamino and its ammonium salt, and vinyl.
  • the electron withdrawing group may be selected from the group consisting of nitro, halo, C 1 -Cg alkylsulfonyl, cyano, trifluoro Ci-C 6 alkoxy, trifluoro C 1 -C 6 alkylthio, C 1 -C 6 alkylcarbonyloxy, nitroso, formyl, C 1 -C 6 alkoxycarbonyl, Ci-C 6 alkylcarbonyl, hydroxy, thiol, sulfamoyl, C 1 -C 6 alkylsulfamoyl, chloro C 1 -C 6 alkyl, amino, hydroxy C 1 -C 6 alkyl, phenyl, N 5 N-C 1 -C 6 dialkylamino, and vinyl, and preferably selected from the group consisting of nitro, halo, methylsulfonyl, cyano, trifluoromethoxy, trifluoromethylthio, acyl
  • the halo group can be fluoro, chloro, bromo, or iodo.
  • a preferred electron-withdrawing group is nitro.
  • a nitrobenzylphenoxycarbamate linker (Carl et al., J Med. Chem. 1981, 24, 479-480) has been shown for doxorubicin prodrugs (Florent et al., J. Med. Chem. 1998, 41, 3572-3581) and 5-fluoruracil prodrugs ( Lougerstay-Madec et al., J. Chem. Soc. - Perkin Trans. 1 1999, 1369-1375) to self-immolate efficiently once the respective glucuronides are cleaved.
  • any suitable inactivator of AGT can be employed in accordance with the present invention.
  • inactivators of AGT include unsubstituted or substituted O 6 - benzylguanine (see formula below), C ⁇ -benzyl-S-azaguanine, O 6 -benzyloxy pyrimidine, and 2,4-diamino-O ⁇ -benzyloxy-5 ⁇ -triazine, preferably an unsubstituted or substituted O 6 - benzylguanine or an unsubstituted or substituted O 6 ⁇ benzyl-2'-deoxyguanosine.
  • the inactivator of AGT is preferably linked through the N 2 -position to the carbonyl of B.
  • the benzyl group of the substituted ⁇ 9 ⁇ -benzylguanine, substituted 0 6 -benzyl-2'- deoxyguanosine, substituted O ⁇ -benzyloxy pyrimidine, substituted O d -benzyl-8-azaguanine, and substituted 2,4-diamino-0 5 -benzyloxy-,s-triazine may have one or more substituents, in place of hydrogen, selected from the group consisting of halogen, hydroxy, aryl, a C 1 -C 8 alkyl substituted aryl, nitro, a polycyclic aromatic alkyl containing 2-4 aromatic rings wherein the alkyl is a C 1 -C 6 , a C 3 -Cg cycloalkyl, a C 2 -C 6 alkenyl, a C 2 -C 6 alkynyl, a Ci-C 6 hydroxyalkyl, a C 1 -Cg alk
  • the C ⁇ -benzylguanine or substituted O 6 - benzylguanine may also include a substituent at the 8- and/or 9-position; the R group in the formula below represents a substituent on the phenyl ring.
  • the 8-position substituent (Ri) may be selected from the group consisting of hydrogen, halo, C 1 -C 4 alkyl, C 1 -C 4 hydroxyalkyl, thiol, C 1 -C 4 alkylthio, trifluoromethylthio, C 1 - C 4 thioacyl, hydroxy, C 1 -C 4 alkoxy, trifluoromethoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, Ci-C 4 acyloxy, amino, C 1 -C 4 aminoalkyl, C 1 -C 4 alkylamino, C 1 - C 4 dialkylamino, trifluoromethylamino, ditrifluoromethylamino, aminomethanesulfonyl, C 1 -C 4 aminoacyl, aminotrifluoromethylcarbonyl, formylamino, nitro, nitroso, C 1 -C 4 alkyldiazo
  • Tautomers may also be used, e.g., the substituent at the 8-position may be an oxo group instead of a hydroxy group.
  • the inactivator of AGT may be an unsubstituted or substituted O ⁇ -benzyl-S-azaguanine, preferably linked through the N 2 - position to the carbonyl of B.
  • the O ⁇ -benzyl-8-azaguanine may also include a substituent R 1 at the 9-position selected from the group consisting Of C 1 -C 4 alkyl, Ci-C 4 alkyloxycarbonyl C 1 -C 4 alkyl, carboxy C 1 -C 4 alkyl, cyano Ci-C 4 alkyl, aminocarbonyl C 1 -C 4 alkyl, hydroxy C 1 -C 4 alkyl, and Ci-C 4 alkyloxy C 1 -C 4 alkyl.
  • R 1 at the 9-position selected from the group consisting Of C 1 -C 4 alkyl, Ci-C 4 alkyloxycarbonyl C 1 -C 4 alkyl, carboxy C 1 -C 4 alkyl, cyano Ci-C 4 alkyl, aminocarbonyl C 1 -C 4 alkyl, hydroxy C 1 -C 4 alkyl, and Ci-C 4 alkyloxy C 1 -C 4 alkyl.
  • the inactivator of AGT may be an unsubstituted or substituted O ⁇ -benzyloxy pyrimidine, preferably linked through the N 2 -position to the carbonyl of B.
  • the C ⁇ -benzyloxy pyrimidine may also include a substituent at its 4- and/or 5- position.
  • the 4-position substituent (R 2 ) may be selected from the group consisting of hydrogen, halo, amino, C 1 -C 4 alkyl, Ci-C 4 hydroxyalkyl, thiol, C 1 -C 4 alkylthio, trifluoromethylthio, C 1 -C 4 thioacyl, hydroxy, Ci-C 4 alkyloxy, trifluoromethoxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, Ci-C 4 acyloxy, Ci-C 4 aminoalkyl, C 1 -C 4 alkylamino, Ci-C 4 dialkylamino, trifluoromethylamino, dMfluoromethylarr ⁇ io, aminomethanesulfonyl, amino Ci-C 4 alkylcarbonyl, aminotrifluoromethylcarbonyl, formylamino, nitro, nitroso, Ci-C 4 alkyldiazo,
  • a preferred example of the prodrug of the present invention is: wherein R is H or , wherein Bn stands for benzyl, which may be optionally substituted as discussed above.
  • the prodrugs may be used as pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, and arylsulfonic acids.
  • An example of arylsulphonic acid isp- toluenesulphonic acid.
  • the carboxyl group of the prodrug may be converted to salts known to those skilled in the art, for example, a salt of an alkali metal (e.g., sodium or potassium), alkaline earth metal (e.g., calcium), or ammonium salt.
  • the present invention further provides a pharmaceutical composition comprising a compound (or prodrug) described above and a pharmaceutically acceptable carrier.
  • the prodrugs of the present invention as described above will be administered in a pharmaceutical composition to an individual afflicted with a cancer. Those undergoing or about to undergo chemotherapy can be treated with the prodrugs separately or in conjunction with other treatments, as appropriate.
  • compositions are administered to a patient in an amount sufficient to elicit an effective depression of AGT activity thereby potentiating the cytotoxicity of the chemotherapeutic treatment.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose,” which is also an “AGT inactivating effective amount.”
  • Amounts effective for a therapeutic or prophylactic use will depend on, e.g., the stage and severity of the disease being treated, the age, weight, and general state of health of the patient, and the judgment of the prescribing physician.
  • the size of the dose will also be determined by the prodrug selected, method of administration, timing and frequency of administration as well as the existence, nature, and extent of any adverse side- effects that might accompany the administration of a particular prodrug and the desired physiological effect.
  • Suitable chemotherapeutic agents administered in coordination with the prodrugs of the present invention include alkylating agents, such as chloroethylating and methylating agents. Such agents may be administered using techniques such as those described in Wasserman et al., Cancer, 36, pp. 1258-1268 (1975) and Physicians' Desk Reference, 58th ed., Thomson PDR (2004). For example, l,3-bis(2-chloroethyl)-l-nitrosourea (carmustine or
  • BCNU Bristol-Myers, Evansville, IN
  • BCNU may be administered intravenously at a dosage of about 40 mg/m 2 when O 6 -benzylguanine is employed.
  • Other alkylating agents may be administered in appropriate dosages via routes of administration known to skilled medical practitioners.
  • Suitable doses and dosage regimens can be determined by conventional range- finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the prodrug. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
  • the present inventive method may involve the administration of about 0.1 ⁇ g to about 50 mg of one or more of the prodrugs per kg body weight of the individual.
  • dosages of from about 10 ⁇ g to about 200 mg of the prodrug would be more commonly used, depending on a patient's physiological response, as determined by measuring cancer-specific antigens or other measurable parameters related to the tumor load of a patient.
  • the prodrugs and compositions of the present invention may be employed in many disease states including life-threatening or potentially life-threatening situations. In view of the relatively less toxic nature of the prodrug, it is possible and may be felt desirable by the treating physician to administer some or substantial excess of the prodrug. Single or multiple administrations of the prodrug can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of AGT-inactivating prodrugs of the invention sufficient to effectively enhance the cytotoxic impact of the chemotherapy.
  • compositions for therapeutic treatment are intended for parenteral, topical, oral or local administration and generally comprise a pharmaceutically acceptable carrier and an amount of the active ingredient sufficient to reduce, and preferably prevent, the activity of the AGT protein.
  • the carrier may be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the prodrug, and by the route of administration.
  • the pharmaceutically acceptable carrier is preferably one that is chemically inert to the prodrug or the active compound and one that has no detrimental side effects or toxicity under the conditions of use.
  • Such pharmaceutically acceptable carriers preferably include saline (e.g., 0.9% saline), Cremophor EL (which is a derivative of castor oil and ethylene oxide available from Sigma Chemical Co., St.
  • a preferred pharmaceutical carrier is polyethylene glycol, such as PEG 400, and particularly a composition comprising 40% PEG 400 and 60% water or saline. The choice of carrier will be determined in part by the particular prodrug chosen, as well as by the particular method used to administer the composition.
  • compositions for parenteral administration that comprise a solution of the prodrug dissolved or suspended in an acceptable carrier suitable for parenteral administration, including aqueous and non-aqueous, isotonic sterile injection solutions.
  • compositions include solutions containing anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • the prodrug may be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol, isopropanol (for example in topical applications), or hexadecyl alcohol, glycols, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol ketals, such as 2,2-dimethyl-l,3-dioxolane-4-methanol, ethers, such as poly(ethyleneglycol) 400, an oil, a fatty acid, a fatty acid ester or glyceride, or an acetylated fatty acid glyceride with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose,
  • Oils useful in parenteral formulations include petroleum, animal, vegetable, and synthetic oils. Specific examples of oils useful in such formulations include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral oil. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.
  • Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts
  • suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene polypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl- ⁇ -aminopropionates, and 2-alkyl- imidazoline quaternary ammonium salts, and (e) mixtures thereof.
  • the parenteral formulations typically will contain from about 0.5% or less to about 25% or more by weight of the active ingredient or prodrug in solution. Preservatives and buffers may be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • HLB hydrophile-lipophile balance
  • parenteral formulations can be presented in unit- dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze- dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.
  • Topical formulations including those that are useful for transdermal drug release, are well known to those of skill in the art and are suitable in the context of the present invention for application to skin.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the prodrug dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the prodrug, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions.
  • liquid solutions such as an effective amount of the prodrug dissolved in diluents, such as water, saline, or orange juice
  • diluents such as water, saline, or orange juice
  • capsules, sachets, tablets, lozenges, and troches each containing a predetermined amount of the prodrug, as solids or granules
  • powders such as powders
  • suspensions in an appropriate liquid such as water, saline, or orange juice
  • Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
  • diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent, or emulsifying agent.
  • Capsule forms can be of the ordinary hard- or soft- shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and cornstarch.
  • Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible excipients.
  • Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising a prodrug in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the prodrug, such excipients as are known in the art.
  • a flavor usually sucrose and acacia or tragacanth
  • pastilles comprising a prodrug in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like containing, in addition to the prodrug, such excipients as are known in the art.
  • the prodrugs of the present invention can be made into aerosol formulations to be administered via inhalation.
  • the prodrugs are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of active prodrug may be about 0.01% to about 20% by weight, preferably about 1% to about 10% by weight.
  • the surfactant must, of course, be nontoxic, and preferably soluble in the propellant.
  • Such surfactants are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride.
  • Mixed esters such as mixed or natural glycerides may be employed.
  • the surfactant may constitute from about 0.1% to about 20% by weight of the composition, preferably from about 0.25% to about 5%.
  • the balance of the composition is ordinarily propellant.
  • a carrier can also be included as desired, e.g., lecithin for intranasal delivery.
  • aerosol formulations can be placed into acceptable pressurized propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. They also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer. Such spray formulations may be used to spray mucosa.
  • the prodrugs may be made into suppositories by mixing with a variety of bases, such as emulsifying bases or water-soluble bases. Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams, or spray formulas containing, in addition to the active ingredient, such carriers as are known in the art to be appropriate.
  • the concentration of the prodrugs of the present invention in the pharmaceutical formulations may vary, e.g., from less than about 1%, usually at or at least about 10%, to as much as 20% to 50% or more by weight, and may be selected primarily by fluid volumes, and viscosities, in accordance with the particular mode of administration selected.
  • a typical pharmaceutical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 100 mg of the prodrug.
  • Actual methods for preparing parenterally administrable prodrugs will be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science (17th ed., Mack Publishing Company, Easton, PA, 1985).
  • the prodrugs of the present inventive method may be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes.
  • Liposomes may serve to target the prodrugs to a particular tissue, such as lymphoid tissue or cancerous hepatic cells. Liposomes can also be used to increase the half- life of the prodrug.
  • Many methods are available for preparing liposomes, as described in, for example, Szoka et al, Ann. Rev. Biophys. Bioeng., 9, 467 (1980) and U.S. Patents 4,235,871, 4,501,728, 4,837,028, and 5,019,369.
  • the present invention has applicability to the treatment of any type of cancer capable of being treated with an antineoplastic alkylating agent which causes cytotoxic lesions at the Opposition of guanine.
  • cancers include, for example, colon tumors, prostate tumors, brain tumors, lymphomas, leukemias, breast tumors, ovarian tumors, lung tumors, Wilms' tumor, rhabdomyosarcoma, multiple myeloma, stomach tumors, soft-tissue sarcomas, Hodgkin's disease, and non-Hodgkin's lymphomas.
  • the present invention further provides a method of enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent that causes cytotoxic lesions at the Opposition of guanine, which method comprises administering to a mammal an effective amount of the prodrug described above and administering to said mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the Opposition of guanine.
  • the tumor cells are necrotic tumor cells which express a ⁇ -glucuronidase enzyme. For example, in ovarian, breast, stomach, lung, and bowel carcinomas - necrosis produces ⁇ -glucuronidase enzyme.
  • the prodrug can be administered as part of prodrug monotherapy (PMT); Bosslet et al., Tumor Targeting 1995, /, 45-50; deGroot et al., Curr. Med. Chem. 2001, 8, 1093- 1122.
  • PMT prodrug monotherapy
  • the enzyme can be administered to the patient, for example, by a targeted delivery.
  • the ⁇ - glucuronidase enzyme can be administered to the patient as a conjugate, such as a conjugate of a humanized F(ab')2 fragment of an anti-CEA antibody and of human ⁇ -glucuronidase (see, e.g., U.S.
  • Patent 5,955,100 or alternatively, by the ADEPT system (U.S. Patent 5,935,995; Bagshawe et al., Br. J. Cancer 1988, 58, 700-703), which is a two-step system in which in a first step an antibody-enzyme conjugate (AEC) is injected intravenously.
  • AEC antibody-enzyme conjugate
  • the AEC is retained in the tumor on account of its tumor selectivity, but excreted from healthy tissues in the course of 2-7 days.
  • the prodrug injected intravenously in the second step is activated to give the drug in the tumor by the enzymatic activity of the AEC.
  • increased drug concentrations are observed in tumor and lower drug concentrations are observed in the healthy tissue in comparison with the standard therapy.
  • the FMPA concept (fusion protein-mediated prodrug activation, U.S. Patent 5,935,995) works similarly to the ADEPT system, in which, instead of the xenogeneic and therefore immunogenic AEC, a nonimmunogenic human fusion protein is employed for the tumor selective prodrug activation.
  • VDEPT vector-dependent enzyme prodrug therapy, U.S. Patent 5,935,995
  • a two-step recombinant DNA mixture prodrugs are also activated in a tumor-selective manner after injection of a vector and expression of a structural gene which codes for an enzyme.
  • the present invention also provides a method of enhancing the effect of an antineoplastic alkylating agent, which alkylates the O 6 -position of guanine residues in DNA, in the chemotherapeutic treatment of cancer in a mammal, particularly a human.
  • the method comprises co-administering to the mammal a cancer-treatment effective amount of an antineoplastic alkylating agent and a chemotherapeutic treatment-enhancing amount of a prodrug in accordance with the present invention.
  • enhancing the effect of an antineoplastic alkylating agent is meant that the antineoplastic alkylating agent has a greater effect in the presence of a prodrug of the present invention than in the absence of the prodrug.
  • an alkyltransferase acts on the inactivator released from the prodrug, it is inactivated and, therefore, is not able to act on the DNA in a cancerous cell that has been alkylated by the antineoplastic alkylating agent. Given that the alkyltransferase is not able to act on the alkylated DNA in a cancerous cell, the DNA in the cancerous cell is not repaired, thereby leading to death of the cancerous cell.
  • coadministering is meant administering the antineoplastic alkylating agent and the prodrug sufficiently close in time such that the prodrug can enhance the effect of the antineoplastic alkylating agent.
  • the prodrug can be administered first and the antineoplastic alkylating agent can be administered second, or vice versa.
  • the prodrug and the antineoplastic alkylating agent can be administered simultaneously.
  • a combination of prodrugs can be administered, and one or more of the prodrugs can be administered in combination with another agent useful in the treatment of cancer.
  • the antineoplastic alkylating agent is administered in a dose sufficient to treat the cancer (e.g., cancer-treatment effective amount of an antineoplastic alkylating agent). Such doses are known in the art (see, for example, the Physicians' Desk Reference (2004)).
  • 1, 3 -bis(2-chloroethyl)-l -nitrosourea can be administered intravenously to a patient at a dosage of from about 150 to 200 mg/m 2 every six weeks.
  • Another alkylating agent namely l-(2-chloroethyl)-3- cyclohexyl-1 -nitrosourea (lomustine or CCNU, Bristol-Myers), can be administered orally at a dosage of about 130 mg/m 2 every six weeks.
  • the prodrug is administered in a dose sufficient to enhance the effect of the antineoplastic alkylating agent (e.g., chemotherapeutic treatment-enhancing amount).
  • a suitable dosage is that which will result in a concentration of the prodrug in the cancerous cells to be treated sufficient to deplete alkyltransferase activity, e.g., from about 10 nM to 200 nM intracellularly, which may require an extracellular concentration of from about 10 ⁇ M to 50 ⁇ M.
  • the dose can be adjusted as necessary to enhance the effect of the antineoplastic alkylating agent.
  • the prodrugs of the present invention are useful in enhancing the effect of any suitable antineoplastic alkylating agent that alkylates the Opposition of guanine residues in DNA.
  • antineoplastic alkylating agents include chloroethylating agents.
  • chloroethylating agents include l-(2-chloroethyl)-3-cyclohexyl-l- nitrosourea (CCNU, lomustine), l,3-bis(2-chloroethyl)-l -nitrosourea (BCNU, carmustine), l-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea (MeCCNU, semustine), and l-(2- cliloroethyl)-3-(4-amino-2-methyl-5-pyrimidinyl)methyl-l-nitrosourea (ACNU).
  • CCNU l-(2-chloroethyl)-3-cyclohexyl-l- nitrosourea
  • BCNU carmustine
  • MeCCNU semustine
  • ACNU l-(2- cliloroethyl)-3-(4-amino-2-methyl-5-pyrimi
  • Such agents have been used clinically against tumors of the central nervous system, multiple myeloma, melanoma, lymphoma, gastrointestinal tumors, and other solid tumors (Colvin and Chabner. Alkylating Agents. In: Cancer Chemotherapy: Principles and Practice. Edited by B.A. Chabner and J. M. Collins, Lippincott, Philadelphia, PA. pp. 276-313 (1990); and McCormick et al., Eur. J. Cancer 26: 207-221 (1990)).
  • Chloroethylating agents which have fewer side effects and are currently under development include l-(2-chloroethyl)-3-(2- hydroxyethyl)- 1 -nitrosourea (HECNU), 2-chloroethylmethylsulfonylmethanesulfonate (Clomesone), and l-[N-(2- chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester (Fotemustine) (Colvin and Chabner (1990), supra; and McCormick et al. (1990), supra).
  • HECNU 2-chloroethylmethylsulfonylmethanesulfonate
  • Fotemustine l-[N-(2- chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester
  • Methylating agents include Streptozotocin (2-deoxy-2-(3-methyl-3-nitrosoureido)-D- glucopyranose), Procarbazine (N-(l-methylethyl)-4-[(2- methylhydrazino)methyl]benzamide), dacarbazine or DTIC (5-(3,3-dimethyl-l-triazenyl)- lH-imidazole-4-carboxamide), and Temozolomide (8-carbamoyl-3-methylimidazo[5.1-d]- 1 ,2,3,5-tetrazin-4-(3H)-one).
  • Temozolomide is active against malignant melanomas, brain tumors and mycosis fungoides. Streptozotocin is effective against pancreatic tumors. Procarbazine is used to treat Hodgkin's disease and brain tumors. DTIC is used to treat melanoma and lymphomas (Colvin and Chabner (1990), supra; and Longo, Semin. Concol. 17: 716-735 (1990)).
  • the antineoplastic alkylating agent can be administered by any route. Conventional means of administration are described in Wasserman et al. ⁇ Cancer 36: 1258- 1268 (1975)) and in Physicians' Desk Reference (2004).
  • the inactivators of AGT e.g., unsubstituted or substituted C ⁇ -benzylguanine, unsubstituted or substituted O 5 -benzyl-2'-deoxyguanosine, O ⁇ -benzyl-8-azaguanine, O 6 - benzyloxy pyrimidine, and (9 6 -benzyloxy-5-triazine can be prepared by methods known to those skilled in the art; see, Moschel et al. patents, e.g., 5,091,430; 5,525,606; and 5,958,932, above.
  • the prodrugs of the invention can be prepared by any suitable method. By way of illustration, prodrugs 1 and 2 can be prepared in accordance with the reactions shown in Scheme 1.
  • Prodrugs containing other AGT inactivators can be prepared by an analogous method.
  • the inactivator such as a O 6 -benzyl-9-[(pivaloyloxy)methyl]-8- azaguanine can be reacted with phosgene.
  • the 2-position substituent of the inactivator is preferably an amino group to enable the reaction with phosgene.
  • This example illustrates a method of synthesis of prodrugs in accordance with an embodiment of the invention.
  • 3',5'-Di-0-acetyl-2'-deoxyguanosine was synthesized by the method of Schaller, et al, J. Amer. Chem. Soc, 1963, 55, 3821-3827.
  • Previously unreported spectroscopic data for this compound are presented below. Unless otherwise stated, all other chemicals were obtained from Sigma or Aldrich and were used without further purification. Melting points were determined using an electrothermal apparatus and are uncorrected. 1 H-NMR spectra were recorded in the indicated solvent with a Varian INOVA 400 MHz spectrometer.
  • the solution was neutralized with 10% acetic acid to produce a viscous suspension that was slowly suction filtered (Whatman #50 filter paper) and allowed to dry.
  • the crude product was purified on a Sephadex LH-20 column eluted with H 2 O methanol (65:35) at a flow rate of 1 mL/min. UV absorption was continuously monitored at 254 nm and fractions (10 mL) were collected. The product (1) eluted in fractions 40-50. Methanol was removed on a rotary evaporator at room temperature. The resulting aqueous solution was lyophilized to provide 1 as a white solid (0.21Og, 64%).
  • EXAMPLE 2 This example illustrates the stability and enzymatic hydrolysis properties of the prodrugs in accordance with an embodiment of the invention.
  • Prodrug purity of the prodrugs was determined by HPLC on a Hewlett-Packard LC 1090 Series II system equipped with a Phenomenex 250 x 4 mm column (5 ⁇ m particle size) eluted isocratically at 1 mL/min with acetonitrile/0.1 M triethylammonium acetate (TEAA), pH 7.0, (3:7). Aliquots (100 ⁇ L) from prodrug solutions were withdrawn and diluted with 100 ⁇ L of a solution of j?-nitrobenzyl alcohol (an internal standard) in acetonitrile/0.1 M TEAA (6:4). UV detection was at 254 and 280 run.
  • TEAA triethylammonium acetate
  • the stability of the prodrugs was determined in phosphate buffered saline (pH 7.2) (Life Technologie, Inc), a Tris buffer containing 50 mM Tris-HCl (pH 7.5) (Life Technologies, Inc), 5 mM dithiothreitol and 0.1 mM EDTA, a MOPS buffer (pH 7.0) containing 50 mM morpholinopropane sulfonic acid, 0.01% bovine serum albumin and 0.01% NaCl and a modified Dulbecco's medium prepared by combining 400 mL of Dulbecco's medium with 7 mL of 7.5% NaHCO 3 , 4 mL of 15 mM glutamine, 2 mL gentamicin and 40 mL of fetal calf serum. Solutions were incubated at 37 0 C and prodrug concentrations were analyzed by HPLC at various times as indicated above.
  • Rate constants for the first-order disappearance of prodrugs were estimated from semi-log plots of the concentration of prodrug as a function of time. Observed first order rate constants for hydrolysis of these prodrugs are presented in Table 1.
  • the spontaneous rate of liberation, for example, in aqueous solutions, of the AGT inactivator is much lower than the rate for ⁇ -glucuronidase catalyzed liberation, for example, about 10 times less, and preferably 100 times less.
  • the spontaneous rate of liberation of the AGT inactivator from the prodrug is low, e.g., about 0.2 to about 0.5% by weight per hour.
  • a PBS Phosphate buffered saline, pH 7.2;
  • b Tris 5OmM Tris-HCl (pH 7.5), 5mM dithiothreitol and 0.ImM EDTA, pH 7.5;
  • MOPS 5OmM morpholinopropane sulfonic acid, pH 7.0, 0.1% bovine serum albumin, 0.01% NaCl;
  • d Dulbecco modified Dulbecco's medium.
  • the decomposition of 1 was faster than that of 2 in all buffers although decomposition rates for both compounds are fairly low. For example, under these aqueous conditions, the average half-time for decomposition of 1 is of the order of 100 days.
  • the enzymatic hydrolysis of the prodrugs was investigated with both E. coli and bovine liver ⁇ -glucuronidase in MOPS buffer at pH 7.0. Prodrugs and p-nitrobenzyl alcohol (HPLC internal standard) were dissolved in the MOPS buffer (pH 7.0) at 37 0 C. Enzymatic cleavage was initiated by adding 0.2 Fishman units of E.
  • This example illustrates certain properties of the prodrugs of the present invention, namely, their ability to inactivate AGT in the presence of ⁇ -glucuronidase, and cell killing.
  • Purified recombinant human alkyltransferase was incubated with different concentrations of prodrugs in 0.5 mL of reaction buffer (50 mM Tris-HCl, pH 7.6, 0.1 mM EDTA, 5.0 mM dithiothreitol) containing 50 ⁇ g of hemocyanin for 30 min at 37 0 C.
  • the bovine liver protein, prodrugs and alkyltransferase were incubated together in the above hemocyanin-containing buffer for 30 min at 37 0 C.
  • the remaining alkyltransferase activity was determined after incubation with a [ 3 H] -methylated calf thymus DNA substrate for 30 min at 37 °C by measuring the [ 3 H]- methylated protein formed, which was collected on nitrocellulose filters. The results were expressed as the percentage of the alkyltransferase activity remaining.
  • the concentration of inhibitor that led to a 50% loss of alkyltransferase activity was calculated from graphs of the percentage of remaining alkyltransferase activity against inactivator concentration.
  • prodrugs 1 and 2 were inactive up to a concentration of 50 ⁇ M (Figure 2) while the ED 50 for O ⁇ - benzylguanine is 0.2 ⁇ M (Pegg et al., Prog. Nucleic Acid Res. MoI Biol. 1995, 51, 167-223).
  • HT29 cell killing by BCNU in combination with the prodrugs 1 and 2 is illustrated in Figure 3. Cells treated for 5 hr with increasing concentrations of prodrugs 1 and 2 were quite resistant to killing after a two-hour exposure to 40 ⁇ M BCNU.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des promédicaments à base d'agents d'inactivation de l'O6-alkylguanine-ADN alkyltransférase (AGT). Ces promédicaments peuvent être clivés par l'enzyme β-glucuronidase, qui est administrée au patient ou produite par des cellules tumorales nécrotiques. Ces promédicaments sont représentés par la formule générale A-B-C. Dans cette formule, A désigne un résidu glucuronosyle lié par son 1-oxygène à un cycle phénylique de B ; B désigne un groupe benzyloxycarbonyle, éventuellement substitué au niveau du cycle par un ou plusieurs groupes accepteurs d'électrons ; et C désigne un agent d'inactivation de l'AGT, tel qu'une O6-benzylguanine ou O6-benzyl-2'-désoxyguanosine substituée ou non substituée, par exemple. L'invention concerne également des compositions pharmaceutiques comprenant un promédicament et un excipient de qualité pharmaceutique, ainsi qu'une méthode permettant d'utiliser ces promédicaments pour renforcer le traitement chimiothérapeutique de cellules tumorales chez un mammifère, tel qu'un humain, par exemple, à l'aide d'un agent d'alkylation antinéoplasique produisant des lésions cytotoxiques au niveau de la position O6- de la guanine.
PCT/US2005/031506 2004-09-08 2005-09-06 Promedicaments a base d'agents d'inactivation de l'o6-alkylguanine-adn alkyltransferase, clivables par la beta-glucuronidase WO2006029065A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2005282562A AU2005282562A1 (en) 2004-09-08 2005-09-06 Beta-glucuronidase cleavable prodrugs of O6-alkylguanine-DNA alkyltransferase inactivators
EP05794349A EP1807438A1 (fr) 2004-09-08 2005-09-06 Promedicaments a base d'agents d'inactivation de l'o6-alkylguanine-adn alkyltransferase, clivables par la beta-glucuronidase
CA002579660A CA2579660A1 (fr) 2004-09-08 2005-09-06 Promedicaments a base d'agents d'inactivation de l'o<sp>6</sp>-alkylguanine-adn alkyltransferase, clivables par la beta-glucuronidase
US11/683,310 US7825096B2 (en) 2004-09-08 2007-03-07 O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60804504P 2004-09-08 2004-09-08
US60/608,045 2004-09-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/683,310 Continuation-In-Part US7825096B2 (en) 2004-09-08 2007-03-07 O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs

Publications (1)

Publication Number Publication Date
WO2006029065A1 true WO2006029065A1 (fr) 2006-03-16

Family

ID=35355287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/031506 WO2006029065A1 (fr) 2004-09-08 2005-09-06 Promedicaments a base d'agents d'inactivation de l'o6-alkylguanine-adn alkyltransferase, clivables par la beta-glucuronidase

Country Status (4)

Country Link
EP (1) EP1807438A1 (fr)
AU (1) AU2005282562A1 (fr)
CA (1) CA2579660A1 (fr)
WO (1) WO2006029065A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109735A2 (fr) * 2007-03-07 2008-09-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inactivateurs de o6-alkylguanine-adn alkyltransférase
WO2008137207A2 (fr) * 2007-05-02 2008-11-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Désactiveurs de o6-alkylguanine-adn alkyltransférase
JP2010535195A (ja) * 2007-08-01 2010-11-18 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 選択的な抗腫瘍薬として有用なピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−グリコシドプロドラッグ
CN104031047A (zh) * 2014-05-28 2014-09-10 北京工业大学 一种新型的具有抗癌活性的氯乙基亚硝基脲及其合成方法
CN104031048A (zh) * 2014-05-28 2014-09-10 北京工业大学 一种新型的β-氯乙基亚硝基脲类化合物及其合成方法和用途
CN106083854A (zh) * 2016-06-20 2016-11-09 北京工业大学 一种低氧激活agt蛋白抑制剂及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561119A (en) * 1991-04-30 1996-10-01 Laboratoires Hoechst Glycosylated prodrugs, their method of preparation and their uses
EP1142893A1 (fr) * 1994-08-01 2001-10-10 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services O6-benzylguanines et 6(4)-benzyloxypyrimidines substituées

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561119A (en) * 1991-04-30 1996-10-01 Laboratoires Hoechst Glycosylated prodrugs, their method of preparation and their uses
EP1142893A1 (fr) * 1994-08-01 2001-10-10 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services O6-benzylguanines et 6(4)-benzyloxypyrimidines substituées

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MADEC-LOUGERSTAY, R. ET AL: "Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy", J. CHEM. SOC., PERKIN TRANS. 1, 1999, pages 1369 - 1375, XP002355977 *
WEI, G. ET AL: "Beta-glucuronidase-cleavable prodrugs of O6-benzylguanine and O6-benzyl-2'-deoxyguanosine", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, 13 December 2004 (2004-12-13), pages 256 - 261, XP002355978 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825096B2 (en) 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
WO2008109735A2 (fr) * 2007-03-07 2008-09-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inactivateurs de o6-alkylguanine-adn alkyltransférase
WO2008109735A3 (fr) * 2007-03-07 2009-01-15 Us Gov Health & Human Serv Inactivateurs de o6-alkylguanine-adn alkyltransférase
WO2008137207A2 (fr) * 2007-05-02 2008-11-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Désactiveurs de o6-alkylguanine-adn alkyltransférase
WO2008137207A3 (fr) * 2007-05-02 2009-02-05 Us Gov Health & Human Serv Désactiveurs de o6-alkylguanine-adn alkyltransférase
US8188055B2 (en) 2007-05-02 2012-05-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inactivators of O6-alkylguanine-DNA alkyltransferase
JP2010535195A (ja) * 2007-08-01 2010-11-18 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ 選択的な抗腫瘍薬として有用なピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−グリコシドプロドラッグ
CN104031047A (zh) * 2014-05-28 2014-09-10 北京工业大学 一种新型的具有抗癌活性的氯乙基亚硝基脲及其合成方法
CN104031048A (zh) * 2014-05-28 2014-09-10 北京工业大学 一种新型的β-氯乙基亚硝基脲类化合物及其合成方法和用途
CN104031048B (zh) * 2014-05-28 2016-03-09 北京工业大学 一种β-氯乙基亚硝基脲类化合物及其合成方法和用途
CN104031047B (zh) * 2014-05-28 2016-03-09 北京工业大学 一种具有抗癌活性的氯乙基亚硝基脲及其合成方法
CN106083854A (zh) * 2016-06-20 2016-11-09 北京工业大学 一种低氧激活agt蛋白抑制剂及其制备方法与应用

Also Published As

Publication number Publication date
AU2005282562A1 (en) 2006-03-16
CA2579660A1 (fr) 2006-03-16
EP1807438A1 (fr) 2007-07-18

Similar Documents

Publication Publication Date Title
ES2233513T3 (es) 6(4)-benciloxipirimidinas sustituidas.
US7825096B2 (en) O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
EP1807438A1 (fr) Promedicaments a base d&#39;agents d&#39;inactivation de l&#39;o6-alkylguanine-adn alkyltransferase, clivables par la beta-glucuronidase
NZ227960A (en) 2&#39;,3&#39;-dideoxy-2&#39;,2&#39;-difluoronucleosides, furyl intermediates and pharmaceutical compositions
US11357828B2 (en) Releasable GLP-1 conjugates
AU747012B2 (en) Preparation of thioarabinofuranosyl compounds and use thereof
AU2007261002B2 (en) Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
US20120149657A1 (en) 2&#39;-fluoro arabino nucleosides and use thereof
EP0576227A2 (fr) 2&#39;-désoxy-2&#39;,2&#39;-difluoro nucléosides puriniques (substitué en positions 2,6 et 8) avec un activité antiviral et anticancer et leurs intermédiaires
US7419965B2 (en) Nucleotide lipid ester derivatives
US8188055B2 (en) Inactivators of O6-alkylguanine-DNA alkyltransferase
JP2002503671A (ja) Ｏ６−ベンジルグアニン含有オリゴデオキシリボヌクレオチドおよびその使用
US8440634B2 (en) Bicyclic derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics
US20070155752A1 (en) 2-Amino-o4-substituted pteridines and their use as inactivators of o6-alkylguanine-dna alkyltransferase
WO2000077014A1 (fr) Phosphates d&#39;aryle

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11683310

Country of ref document: US

Ref document number: 2579660

Country of ref document: CA

Ref document number: 2005282562

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005794349

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005282562

Country of ref document: AU

Date of ref document: 20050906

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005282562

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005794349

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11683310

Country of ref document: US